From my understanding that if you go to different lab that you really can't make a comparison.
And I suspect that at the same lab you could get tests day after day and see fluctuations of more from 0.028 and 0.0030.
I know nothing of you history or age, but for me I would be concerned, but not really worried until I saw 0.20. And then I would be figuring out if it was the right time or to wait to see how long it took to double or to wait for 0.4 or ?View Thread
During sexual arousal each gland produces a clear, salty, viscous secretion known as pre-ejaculate . This fluid helps to lubricate the urethra for spermatozoa to pass through, neutralizing traces of acidicurine in the urethra,[2> and helps flush out any residual urine or foreign matter. Though the pre-ejaculate does not contain sperm it is possible for this fluid to pick up sperm , remaining in the urethral bulb from previous ejaculations , and carry them out prior to the next ejaculation.
I had a prostatectomy and get small amount of fluid via that gland.
Don't know if that is what you are getting or not.View Thread
Different labs use different methods and different levels of detectability.
I used to get my test through my urologist who used LabCorp. I never saw the actual report, just "Undetectable" from the doctor.
The last one was through my PCP and he used Quest Diagnostics. And I got a copy of the actual lab report.
It is shows <0.02. And has these comments "PSA values obtained with different assay methods or kits can not be used interchaneably". Along with a statement that limit of accuracy for there test is 0.02.
Also there is a note that reagent was changed on 2/3/13 and the new lower level is 0.02 I have not idea of what is was before that from Quest.
Also this needs to be a Post-Prostatectomy PSA, which is a high sensitivity test, and it is different from the standard PSA.
I had to educate my PCP on the difference.
http://www.ncbi.nlm.nih.gov/pubmed/16921049 CONCLUSION: BCR defined as a PSA value of at least 0.4 ng/mL followed by another increase best explains the development of distant metastasis among 10 candidate definitions, after controlling for clinical variables and the use of secondary therapy. On the basis of this evidence, we propose that this definition be adopted as the standard for reporting the outcome of RP.